Vaxxas Chair Sarah Meibusch said, “The TGA manufacturing licence marks a significant milestone for Vaxxas as we progress toward commercialising our HD-MAP technology. By reducing cold-chain ...

Orelabrutinib demonstrated outstanding efficacy and well-tolerated safety profile in patients with SLE who had received 48 weeks of treatment in the phase IIb study. A total of 187 patients were ...

CARDAMYST nasal spray is a novel and rapid-acting calcium channel blocker delivered when needed to treat often highly symptomatic and unpredictable episodes of PSVT. With CARDAMYST, adults with PSVT ...

The global clinical trial technology market is projected to reach USD 22.7 billion by 2030, expanding at a compound annual growth rate (CAGR) of 8.3%. Within this, AI-enabled patient recruitment ...

Genesis shares interested parties’ focus on patients, residents and staff, and the importance of safeguarding access to high-quality post-acute care in the communities served by the more than 170 ...

The aggregate gross proceeds to the Company from the offering were approximately $8.0 million before deducting the placement agent's fees and other offering expenses payable by the Company. The ...

As per previous communication, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had informed Anavex about a negative trend-vote following its oral examination in ...

CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to ...

The GMP batch was successfully produced using Zelluna’s proprietary manufacturing process, which was finalised and locked in April 2025. The process is designed to deliver high-quality TCR-NK products ...

Emergent BioSolutions (NYSE: EBS) today announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental Biologics License Application (sBLA) for its Winnipeg, Canada facility ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of December 2025, which is payable ...

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: ...